fda approves first oral glp-1 obesity drug august 21 2025 US accepts Novo Nordisk's application for Wegovy for weight loss Novo's Wegovy Inches Closer to

Special Introductory Offer Get 10% off your first visit Experience our services with 10% off your first visit your introduction to personalized care.

Surgical Risk: The use of GLP-1s can slow stomach emptying, which may pose risks (e.g., aspiration) during anesthesia if the medication is not paused prior to surgery

Examples cited by FDA include the following statements: [A] proven medication Clinically studied and shown to deliver powerful results when combined with healthy habits "from the same family as GLP-1 treatments like Mounjaro and Zepbound and It contains the same active ingredient as FDA-approved medications Per FDA, claims such as the above examples imply that these compounded drugs have been reviewed and approved by the Agency, or that they have been shown to be safe and effective, when they have not

Medicare Coverage Limitations Medicare coverage of obesity services and treatments currently includes obesity screening, behavioral counseling, and bariatric surgery but does not include drugs prescribed for weight loss